Day-one subcutaneous Leqembi lets eligible early Alzheimer's patients start treatment at home in 2026 without prior IV infusions. Leqembi, or lecanemab-irmb, is an anti-amyloid drug for mild cognitive impairment or mild dementia due to Alzheimer's. Use this checklist to confirm amyloid status, ApoE gene risk, MRI timing, medicines, and home support. According to the FDA approval notice from Eisai U.S., the once-weekly initiation dose removes the need to begin with clinic infusions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can start treatment at home?
- What testing comes before dose one?
- How does weekly dosing work?
- How do you stay safe after starting?
Who can start treatment at home?
Treatment is only for mild cognitive impairment or mild dementia due to Alzheimer's. Amyloid-beta pathology must be confirmed by PET scan or spinal-fluid testing before the first dose. A doctor must confirm the diagnosis fits this early stage.
More advanced dementia does not qualify. Ask what test proved amyloid in your case. Coverage rules narrow the group further. According to the April 2026 CareSource TRICARE policy document, recent TIA, stroke, seizures, MRI contraindications, bleeding disorders, or anticoagulant use can exclude patients.
What testing comes before dose one?
Plan for two key checks: ApoE gene testing with counseling, and a recent baseline brain MRI. The drug label carries a boxed warning for amyloid-related imaging abnormalities, called ARIA. ARIA includes swelling, called ARIA-E, and bleeding, called ARIA-H. These events can be serious, fatal, or mimic stroke.
People with two copies of the ApoE epsilon 4 gene face higher incidence and should be tested first. Discuss personal risk before consent. Ask how your clinic handles ARIA symptoms after hours. Bring a caregiver to this visit to hear warning signs directly.
How does weekly dosing work?
The initiation regimen is 500 mg once weekly, given as two 250-mg autoinjector shots. Eisai and Biogen report in the BioSpace press release that each injection takes about 15 seconds, with U.S. launch planned for late August 2026. Earlier, the 360-mg weekly shot was only for maintenance after 18 months of IV lecanemab.
Patients may now use under-the-skin dosing for both initiation and maintenance. Confirm which dose your prescription lists. Preparation shifts from infusion scheduling to home-injection training. Practice storage, injection sites, missed-dose rules, and sharps disposal. Set a fixed weekly day with reminders and backup help.
How do you stay safe after starting?
Schedule brain MRIs after 1, 2, 3, and 6 months, plus a recent baseline scan. Dosing decisions depend on ARIA type, severity, and symptoms.
Review all blood thinners, antiplatelet drugs, NSAIDs, and supplements now. Antithrombotic use raises brain-bleed risk on lecanemab, so do not start or stop these drugs without the prescribing team. Carry an updated medicine list to every visit.
- Confirm amyloid PET or spinal-fluid result is on file
- Complete ApoE testing, baseline MRI, and medicine review
- Arrange injection training and a weekly caregiver check-in
- Save the ARIA symptom plan and MRI dates before late-August availability
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
- Cannabis for Dementia Agitation Monitoring Checklist for Alzheimer’s Patients and Caregivers
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
